Brain and Central Nervous System Tumors Clinical Trial
Official title:
Complimentary Hyperbaric Oxygen for Brain Radionecrosis
RATIONALE: Hyperbaric oxygen may increase blood flow and decrease swelling in areas of the
brain damaged by radiation therapy. Giving hyperbaric oxygen therapy together with
dexamethasone may be an effective treatment for radiation necrosis of the brain.
PURPOSE: This randomized clinical trial is studying how well hyperbaric oxygen therapy works
in treating patients with radiation necrosis of the brain.
OBJECTIVES:
- Obtain pilot data demonstrating the potential for increased benefit when complementing
conventional steroid therapy with adjunctive hyperbaric oxygen therapy (HBOT) in
patients with brain radionecrosis.
- Estimate the magnitude of benefit of HBOT using objective measures of neurologic
function, radiographic imaging, and standardized quality of life measures in these
patients.
- Determine, preliminarily, the effect of HBOT on cerebral revascularization using
perfusion MRI in these patients.
- Determine the feasibility of performing a large-scale, randomized, controlled study
(particularly with regard to patient recruitment and retention) comparing HBOT with
conventional steroid therapy.
OUTLINE: This is a pilot, randomized, controlled study. Patients are randomized to 1 of 2
treatment arms.
- Arm I (conventional care only): Patients receive baseline steroid therapy comprising
oral dexamethasone 4 times daily. Steroid doses are either increased or decreased per
standard protocol during the 90-day treatment period. Patients who demonstrate
neurological deterioration at each evaluation (as evidenced by a decrease in Karnofsky
performance status score) receive escalating doses of dexamethasone until the maximum
daily dose of 32 mg is reached. Patients who reach the maximum daily dose of
dexamethasone are removed from the study. Patients also receive anticonvulsant therapy
during study therapy.
- Arm II (conventional care and hyperbaric oxygen therapy [HBOT]): Patients receive
conventional care as in arm I*. Patients also undergo HBOT once daily, 5 days a week,
for 90 days (60 treatments total).
NOTE: *Patients in arm II who reach the maximum daily dose of dexamethasone are not removed
from the study.
- Cerebral revascularization study: Five patients from each arm are randomly selected to
undergo perfusion MRI before treatment and within 1 week after completion of study
therapy to determine the proportion of cerebral neovascularization in each arm.
Patients are evaluated during study by standardized physical examinations, positron emission
tomography scans, perfusion MRI, complete neurologic assessment, and standardized,
health-related quality of life measures at baseline, at 30-day intervals during treatment,
at the end of treatment, and at 1, 2, and 4 months after completion of study therapy.
After completion of study therapy, patients are followed at 1, 2, and 4 months.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
;
Allocation: Randomized, Masking: Single Blind, Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 | |
Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 | |
Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 |